Adult Glioblastoma: Strategies, Challenges, and Opportunities
Posted on: Monday, 24 March 2008, 15:00 CDT
HADDON HEIGHTS, N.J., March 24 /PRNewswire/ -- Glioblastomas are the most common and most malignant type of glioma. Healthcare professionals face many challenges in the treatment of glioblastoma as therapy remains largely palliative, and mean length of survival in patients is less than one year.
Recent clinical trials have shown that combining surgery, radiation therapy and chemotherapy extends survival in a subset of patients, particularly when the chemotherapeutic agent temozolomide is included in the treatment approach. Other potentially promising therapies for glioblastoma under investigation include regional drug administration, targeted biological therapies, vaccines, and genomic profiling. As research continues, new agents for adult glioblastoma are expected to further extend survival.
To address the need for current education on glioblastoma, treatment strategies, challenges, and emerging therapies, Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine (PIM) are jointly sponsoring a series of complimentary live educational lectures in institutions across the United States, as well as an online educational activity consisting of a virtual lecture presentation.
The Course Director for this continuing education opportunity is Dr. Marc C. Chamberlain, Professor of Neurology at the University of Washington and expert in the development of clinical trials for primary brain tumors. All lectures will be presented by experts in the treatment of glioblastoma. Continuing education credit will be offered for physicians, pharmacists and nurses.
Healthcare professionals can schedule a live lecture at their institution by contacting RMEI:
Online: http://www.rmei.com/GBLectures Toll-free Phone: 1-866-770-7634, ext. 337 Email: GBLectures@rmei.com
This continuing education opportunity is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute of Medicine and is supported by an educational grant from Schering-Plough.
Robert Michael Educational Institute LLC is a full-service medical education company dedicated to providing comprehensive medical education to healthcare providers, patients, and caregivers. Our mission is to design programs that improve diagnosis and treatment through a variety of educational programming such as national and international symposia, teleconferences, live meetings, enduring print materials, and interactive Internet programs.
Robert Michael Educational Institute LLC
CONTACT: Erin McCabe, +1-856-547-4141 ext. 226, for Robert MichaelEducational Institute LLC
Web site: http://www.rmei.com/GBLectures
Source: PRNewswire
Related Articles
- Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients
- Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
- Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- New Non-Invasive Treatment Option for Lung Cancer Patients Offered By CyberKnife Center of Miami
- Somaxon Pharmaceuticals to Announce Results of Phase 3 Clinical Trial of SILENOR(TM) for the Treatment of Insomnia in Elderly Patients and Host Conference Call
- FDA Approves Keppra(R) As Adjunctive Therapy in the Treatment of Myoclonic Seizures in Patients With Juvenile Myoclonic Epilepsy
- New Global Asthma Survey Reveals Serious Communication and Treatment Barriers Between U.S. Physicians and Patients
- Clinical Characteristics and Treatment Responses of Tuberculosis in Patients With Malignancy Receiving Anticancer Chemotherapy*
- Evaluation of and Treatment Considerations for the Dental Patient With CARDIAC Disease
 |
 |
User Comments (0)
RSS Feeds